Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers (DFUs)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03855514|
Recruitment Status : Recruiting
First Posted : February 26, 2019
Last Update Posted : May 26, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Foot Ulcer||Other: NuShield||Not Applicable|
Two hundred (200) subjects with a chronic DFU ranging in size from 0.5cm2 and 25 cm2 will be randomized 1:1 to either NuShield® and SOC or SOC alone following the 14 day screening period. Following screening and randomization, subjects shall be seen weekly for up to 24 weeks. For subjects that heal prior to week 24, a healing confirmation visit shall occur two weeks later to confirm maintenance of complete wound closure.
Subjects that are randomized into the SOC group whose DFU has not healed by week 12 may be crossed over to receive NuShield® and followed for an additional 12-14 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Multicenter, Randomized, Controlled Clinical Study Of NuShield® and Standard of Care (SOC) Compared to SOC Alone For The Management Of Diabetic Foot Ulcers|
|Actual Study Start Date :||February 8, 2019|
|Estimated Primary Completion Date :||November 2021|
|Estimated Study Completion Date :||December 30, 2021|
Active Comparator: NuShield
NuShield® is a sterile, dehydrated placental allograft
NuShield® is a dehydrated placental allograft.
No Intervention: Standard of Care
Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
- Length of time that a wound achieves complete wound closure (CWC) [ Time Frame: 12 weeks ]Duration (number of days) to achieve CWC from baseline to week 12 assessed between both groups
- Greater than 40% wound closure at week 4 from baseline [ Time Frame: 4 weeks ]Proportion of subjects achieving ≥ 40% wound closure at Week 4 from baseline
- Change in wound area [ Time Frame: 12 weeks ]Mean percent change from baseline in wound area at Week 12
- Incidence of prescribed pain and/or neuropathic medications [ Time Frame: 12 weeks ]Cumulative amount of pain and neuropathic medications taken between baseline and Week 12 assessed between both groups.
- Reduction in subject reported pain at week 12 from baseline assessed between both groups via the Numeric Pain Rating Scale (NPRS) [ Time Frame: 12 weeks ]Mean percent change at week 12 in subject reported pain, assessed via the NPRS pain scale where 0 = no pain and 10 = worst pain imaginable, on a scale of 0 to 10.
- Utilization of healthcare resources assessment [ Time Frame: 12 weeks ]Utilization of healthcare resources through Week 12
- Improvement in subject reported quality of life at week 12 from baseline assessed via the Wound-QoL (Questionnaire on quality of life with chronic wounds). [ Time Frame: 12 weeks ]Mean percent change at week 12 from baseline in subject reported quality of life scores between both groups. The 17 item Wound-QoL tool measures the disease-specific, health-related quality of life of patients with chronic wounds. A global score is computed by averaging all 17 items where subjects answer each question on a scale of 0 to 4, where 0=not at all and 4=very much.
- Time to complete wound closure (CWC) by or on 24 weeks [ Time Frame: 24 weeks ]Length of time wounds achieve CWC at week 24 from baseline
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 85 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- At least 18 years old and maximum of 85 years old.
- Subjects with a diabetic foot ulcer that is either superficial, e.g. not involving tendon, capsule, or bone; or wounds that penetrate into tendon, capsule, bone and/or joint.
- Subjects, with the presence of Diabetes, must have a Glycosylated hemoglobin (HbA1c) ≤ 12% within 4 weeks prior to randomization
- Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to the initial screening visit with no upper limit in duration of non-healing.
- Subject has adequate circulation to the foot as documented by either: Skin perfusion pressure (SPP) measurement of ≥ 45 mmHg, Toe-brachial index (TBI) ≥ 0.6/ Toe pressure greater than 40, Ankle-brachial index (ABI) between 0.60 and ≤ 1.3
- Index ulcer is a minimum of 0.5 cm2 and a maximum of 25cm2 at randomization, prior to first study treatment.
- The index ulcer has been offloaded for 14 days prior to randomization.
- Index ulcer has not reduced in area > 20% from Day -14 to Day 0, prior to randomization.
- Subject understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
- Subject, or their Legally Authorized Representative (LAR), has read, understood, and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken.
- Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes.
- Treatment with HBO wound dressings that include growth factors, bioengineered tissues, or skin substitutes within 30 days of randomization.
- History of bone cancer or metastatic disease of the affected limb or chemotherapy within the 12 months prior to randomization.
- Subjects with a history of more than two weeks treatment with immunosuppressants (including prednisone 10 mg daily or an equivalent does of other oral steroids cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to first Screening Visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
- Subject is on any investigational drug(s) or therapeutic device(s) within 30 days preceding the first Screening Visit.
- History of radiation at the ulcer site.
- Index ulcer has been previously treated or will need to be treated with any prohibited therapies within 30 days prior to randomization.
- Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment.
- Active infection at the index ulcer at the time of Randomization.
- Acute osteomyelitis or bone infection of the affected foot, where subject has received less than 4 weeks of systemic antibiotics at the time of Screening and less than 6 weeks prior to Randomization (systemic antibiotic regimen must be completed at the time of Randomization).
- Subject's with suspected infection who have received less than 2 weeks of systemic antibiotics, or have not had surgical resection of clinically diagnosed osteomyelitis
- Subjects with suspected osteomyelitis who have not had an X-ray, CT scan or MRI within 14 days prior to Randomization.
- Subject is unwilling or unable to comply with the study requirement for offloading the index wound
- Subject is pregnant or breast feeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03855514
|Contact: Galen Hale||(205) 541-9682||GHale@organo.com|
|Contact: Andrea Black||(781) 830-2364||ABlack@organo.com|
|United States, California|
|ILD Research Center||Recruiting|
|Carlsbad, California, United States, 92002|
|Contact: Eric Martinez firstname.lastname@example.org|
|Principal Investigator: Dean Vayser, DPM|
|Limb Preservation Platform||Recruiting|
|Fresno, California, United States, 94063|
|Contact: Destiny Blackstone email@example.com|
|Principal Investigator: Shawn Cazzell|
|University of Southern California||Recruiting|
|Los Angeles, California, United States, 91208|
|Contact: Karen DHuyvetter Karen.DHuyvetter@med.usc.edu|
|Principal Investigator: David Armstrong|
|Redwood City, California, United States, 94063|
|Contact: Shannon Meyer firstname.lastname@example.org|
|Principal Investigator: Geoffrey Gurtner|
|United States, Connecticut|
|Family Foot & Ankle Specialists||Recruiting|
|Bridgeport, Connecticut, United States, 06606|
|Contact: Catherine Porter email@example.com|
|Principal Investigator: Daniel Davis|
|United States, Florida|
|Doctors Research Network||Recruiting|
|Miami, Florida, United States, 33143|
|Contact: Nara Neiva firstname.lastname@example.org|
|Principal Investigator: Jason Hanft|
|United States, Georgia|
|Roswell, Georgia, United States, 30076|
|Contact: Amelia Sobhani email@example.com|
|Principal Investigator: Ira Kraus|
|United States, New York|
|NYU Winthrop Hospital||Recruiting|
|New York, New York, United States, 11501|
|Contact: Helen Yiu firstname.lastname@example.org|
|Principal Investigator: Scott Gorenstein|
|United States, Texas|
|Futuro Clinical Trials||Recruiting|
|McAllen, Texas, United States, 78501|
|Contact: Chrissy Rodriguez email@example.com|
|Principal Investigator: Joseph Caporusso|
|Study Director:||Christine McLennan||Organogenesis Inc.|
|Other Study ID Numbers:||
|First Posted:||February 26, 2019 Key Record Dates|
|Last Update Posted:||May 26, 2021|
|Last Verified:||May 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Chronic Diabetic Foot Ulcer
Endocrine System Diseases